Loading cancer entity…
Loading cancer entity…
Clinical trials
8,119 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,288)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07537049 | BR101 in Patients With Relapsed/Refractory Multiple Myeloma | not yet recruiting | Phase 1 | 10 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT07493330 | Genotype-guided Targeted Agents Plus EZH2i for Primary Refractory PTCL | not yet recruiting | Phase 1 / Phase 2 | 86 | Ruijin HospitalOTHER | 0 | Apr 7, 2026 | clinicaltrials |
| NCT07510100 | Eque-cel for the Treatment of Patients With Relapsed/Refractory Multiple Myeloma(FUMANBA-04) | not yet recruiting | Phase 1 / Phase 2 | 17 | Nanjing IASO Biotechnology Co., Ltd.INDUSTRY | 1 | Apr 3, 2026 | clinicaltrials |
| NCT07441954 | Pomalidomide Combined With Obinutuzumab in the Treatment of Patients With Relapsed/Refractory Indolent Lymphoma(GP-1) | not yet recruiting | Phase 1 / Phase 2 | 53 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Mar 2, 2026 | clinicaltrials |
| NCT07421856 | Phase I/II Study of SENL103 for Relapsed or Refractory Multiple Myeloma: A Multicenter, Open-Label, Single-Arm Trial. | not yet recruiting | Phase 1 / Phase 2 | 24 | Hebei Senlang Biotechnology Inc., Ltd.INDUSTRY | 0 | Feb 19, 2026 | clinicaltrials |
| NCT07407010 | BCMA/CD3 Bispecific Antibody as Bridging Therapy Before CAR-T Cell Infusion in RRMM(CM336-001) | not yet recruiting | Phase 1 | 10 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Feb 12, 2026 | clinicaltrials |
| NCT07398638 | Lisatoclax Plus R-CHOP or Pola-R-CHP in Untreated DLBCL: A Phase Ib/II Study | not yet recruiting | Phase 1 / Phase 2 | 122 | Sun Yat-sen UniversityOTHER | 1 | Feb 10, 2026 | clinicaltrials |
| NCT07400744 | A Study to Compare the PK , Safety, and Immunogenicity of QL2109 With Daratumumab in Male Subjects | not yet recruiting | Phase 1 | 102 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 0 | Feb 10, 2026 | clinicaltrials |
| NCT07339527 | EZH2 Inhibitor Zeprumetostat in Combination Therapy for Patients With Relapsed or Refractory Mature T-cell and NK-cell Lymphomas | not yet recruiting | Phase 1 / Phase 2 | 60 | Sun Yat-sen UniversityOTHER | 0 | Jan 14, 2026 | clinicaltrials |
| NCT07334574 | Clinical Study of XP-006 mRNA Vaccine for R/R B-NHL(XP-006) | not yet recruiting | Phase 1 | 20 | Ruijin HospitalOTHER | 1 | Jan 13, 2026 | clinicaltrials |
| NCT07209163 | Combination Therapy With Tazemetostat in Relapsed and Refractory Peripheral T-cell Lymphoma | not yet recruiting | Phase 1 / Phase 2 | 48 | Ruijin HospitalOTHER | 0 | Oct 6, 2025 | clinicaltrials |
| NCT06979076 | A Phase Ib Study of the Selective PKC-β Inhibitor MS-553 in Patients With Refractory or Relapsed CLL/SLL | not yet recruiting | Phase 1 / Phase 2 | 12 | MingSight Pharmaceuticals, IncINDUSTRY | 0 | Sep 29, 2025 | clinicaltrials |
| NCT07107204 | A Clinical Study of BT02 in Patients With Relapsed or Refractory Hematologic Malignancies | not yet recruiting | Phase 1 / Phase 2 | 116 | Biotroy TherapeuticsINDUSTRY | 0 | Sep 17, 2025 | clinicaltrials |
| NCT07169565 | Ibrutinib Followed by BR (Bendamustine and Rituximab) as a Time-Limited Therapy for Waldenström Macroglobulinemia | not yet recruiting | Phase 1 | 21 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Sep 11, 2025 | clinicaltrials |
| NCT07159906 | Homoharringtonine, BCL-2 Inhibitor, Rituximab, and Prednisone in Relapsed/Refractory Diffuse Large B-Cell Lymphoma | not yet recruiting | Phase 1 / Phase 2 | 62 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Sep 8, 2025 | clinicaltrials |
| NCT07139353 | Linperlisib Combined With Chidamide in the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma | not yet recruiting | Phase 1 / Phase 2 | 54 | Sun Yat-sen UniversityOTHER | 0 | Aug 24, 2025 | clinicaltrials |
| NCT07035379 | A Phase I/II Study of TRS005 in Combination With Cyclophosphamide, Doxorubicin, and Prednisone（T-CHP） in Previously Untreated Patients With CD20-positive DLBCL | not yet recruiting | Phase 1 / Phase 2 | 66 | Zhejiang Teruisi Pharmaceutical Inc.INDUSTRY | 1 | Aug 22, 2025 | clinicaltrials |
| NCT07113496 | RN1201injection for Relapsed/Refractory CD19+/BCMA+ Hematologic Malignancies | not yet recruiting | Phase 1 | 27 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Aug 13, 2025 | clinicaltrials |
| NCT07117305 | CD7 CAR-T Combined With Autologous Hematopoietic Stem Cell Transplantation | not yet recruiting | Phase 1 / Phase 2 | 38 | Zhengzhou UniversityOTHER | 1 | Aug 12, 2025 | clinicaltrials |
| NCT07114432 | RN1201 Injection in Newly Diagnosed High-Risk Cytogenetic Multiple Myeloma | not yet recruiting | Phase 1 | 19 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Aug 11, 2025 | clinicaltrials |
| NCT07090954 | A Study of GR1803 Injection in Combination With Anti-CD38 Monoclonal Antibody for the Treatment of Participants With Multiple Myeloma | not yet recruiting | Phase 1 / Phase 2 | 32 | Genrix (Shanghai) Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 29, 2025 | clinicaltrials |
| NCT07068906 | A Clinical Study Exploring CT1194C in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma | not yet recruiting | Phase 1 | 27 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Jul 16, 2025 | clinicaltrials |
| NCT06385522 | A Clinical Trial in Adults With Non-Hodgkin Lymphoma (NHL), With a Particular Emphasis on Cutaneous T Cell Lymphoma (CTCL), Testing the Safety and Activity of a Novel Drug to Inhibit a Protein Called Tumor Necrosis Factor Receptor 2 That Drives Both Lymphoma Growth and Escape of the Immune System | not yet recruiting | Phase 1 | 37 | Boston Immune Technologies and TherapeuticsINDUSTRY | 0 | Jul 8, 2025 | clinicaltrials |
| NCT07032324 | A Clinical Study Exploring CT1190B in the Treatment of Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma ( CT1190B-CG1101 )(CT1190B) | not yet recruiting | Phase 1 | 27 | Qian WenbinOTHER | 1 | Jun 23, 2025 | clinicaltrials |
| NCT07024147 | JWCAR239 in Patients With B Cell Non-Hodgkin Lymphoma | not yet recruiting | Phase 1 | 20 | Peking University Cancer Hospital & InstituteOTHER | 1 | Jun 17, 2025 | clinicaltrials |
| NCT06913179 | CAR-T Cell Therapy Combined With Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed or Refractory Multiple Myeloma(CAR-T-allo) | not yet recruiting | Phase 1 | 30 | Xuzhou Medical UniversityOTHER | 0 | Apr 6, 2025 | clinicaltrials |
| NCT06913192 | Efficacy of Sequential BCMA CAR-T Cell Therapy Following Autologous Hematopoietic Stem Cell Transplantation in Transplant-eligible Newly Diagnosed Multiple Myeloma(AUTO-CAR-T) | not yet recruiting | Phase 1 | 50 | Xuzhou Medical UniversityOTHER | 0 | Apr 6, 2025 | clinicaltrials |
| NCT06894693 | A Phase I Clinical Trial of RS001 in Patients with Relapsed/Refractory B-Cell Malignancies | not yet recruiting | Phase 1 | 13 | Guangdong Ruishun Biotech Co., LtdINDUSTRY | 0 | Mar 25, 2025 | clinicaltrials |
| NCT06845241 | Evaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma | not yet recruiting | Phase 1 / Phase 2 | 68 | Beijing InnoCare Pharma Tech Co., Ltd.INDUSTRY | 1 | Feb 25, 2025 | clinicaltrials |
| NCT06799676 | A Phase Ib/II Clinical Study on the Application of Linperlisib Combined with the VRD Regimen in Newly Diagnosed Patients with Multiple Myeloma | not yet recruiting | Phase 1 / Phase 2 | 42 | Fuling ZhouOTHER | 1 | Jan 29, 2025 | clinicaltrials |
| NCT06757387 | Chidamide Plus Golidocitinib in Relapsed/Refractory Peripheral T-Cell Lymphoma | not yet recruiting | Phase 1 / Phase 2 | 45 | Peking University Cancer Hospital & InstituteOTHER | 0 | Jan 3, 2025 | clinicaltrials |
| NCT06712173 | Linperlisib Combined With EZH2 Inhibitor in Relapsed/Refractory Peripheral T-cell Lymphoma (PTCL) | not yet recruiting | Phase 1 | 33 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Dec 2, 2024 | clinicaltrials |
| NCT06705725 | Phase I Clinical Study of CBG002 CAR-T Cell in Treatment of Relapsed/refractory Multiple Myeloma | not yet recruiting | Phase 1 | 38 | Carbiogene Therapeutics Co. Ltd.INDUSTRY | 0 | Nov 26, 2024 | clinicaltrials |
| NCT06655519 | An Exploratory Study of RD140 Injection in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia | not yet recruiting | Phase 1 | 12 | Peking University People's HospitalOTHER | 0 | Oct 23, 2024 | clinicaltrials |
| NCT06500507 | A Study of QLS4131 in Patients With Recurrent or Refractory Multiple Myeloma | not yet recruiting | Phase 1 | 90 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 15, 2024 | clinicaltrials |
| NCT05982275 | Trial of an Investigational Drug After Rejecting the Relapse of an Allogeneic Transplant(CARTemis-1) | not yet recruiting | Phase 1 / Phase 2 | 25 | Fundación Pública Andaluza para la gestión de la Investigación en SevillaOTHER | 1 | May 14, 2024 | clinicaltrials |
| NCT06333509 | Anti-GPRC5D CAR-T Cells (CT071) in Participants With RRMM or RRpPCL | not yet recruiting | Phase 1 / Phase 2 | 166 | CARsgen Therapeutics Co., Ltd.INDUSTRY | 0 | Mar 27, 2024 | clinicaltrials |
| NCT06318884 | A First-in-human Study of SCTB35 in Patients With Relapse/Refractory B-cell Non-Hodgkin Lymphoma | not yet recruiting | Phase 1 | 76 | Sinocelltech Ltd.INDUSTRY | 1 | Mar 22, 2024 | clinicaltrials |
| NCT06314828 | A Tolerability, Safety and Efficacy Study of RJMty19 in Subjects With Relapsed or Refractory B-NHL | not yet recruiting | Phase 1 | 30 | Guangdong Ruishun Biotech Co., LtdINDUSTRY | 0 | Mar 18, 2024 | clinicaltrials |
| NCT05581875 | A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Pomalidomide and Dexamethasone in Patients With Relapsed/ Refractory Multiple Myeloma Previously Treated With One Line Therapy Who Are Lenalidomide Refractory | not yet recruiting | Phase 1 / Phase 2 | 48 | Hellenic Society of HematologyOTHER | 0 | Oct 17, 2022 | clinicaltrials |
| NCT05181501 | A Study of Fully Human BCMA CAR-T (CT103A) in Patients With Newly Diagnosed High-risk Multiple Myeloma (FUMANBA-2) | not yet recruiting | Phase 1 | 20 | Nanjing IASO Biotechnology Co., Ltd.INDUSTRY | 1 | Jan 6, 2022 | clinicaltrials |
| NCT05091541 | A Phase 1/2 Study of CT120 in Patient With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma | not yet recruiting | Phase 1 / Phase 2 | 125 | Nanjing IASO Biotechnology Co., Ltd.INDUSTRY | 0 | Oct 25, 2021 | clinicaltrials |
| NCT05055791 | A Study to Evaluate the Safety and Tolerance of SYHX1903 in Patients With Relapsed/Refractory Hematologic Malignancies | not yet recruiting | Phase 1 / Phase 2 | 312 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 0 | Sep 24, 2021 | clinicaltrials |
| NCT04856137 | A Phase I/II Study of Diffuse Large B-cell Lymphoma(DLBL) | not yet recruiting | Phase 1 / Phase 2 | 74 | National Health Research Institutes, TaiwanOTHER | 0 | Apr 23, 2021 | clinicaltrials |
Data updated 22 days agoSource updated Apr 17, 2026source: clinicaltrials